Long-term mortality in pediatric sepsis: a systematic review and meta-analysis.

Ann MedJan 19, 2026 (epub)
Clinical ResearchPediatricsOpen access

Yongbiao Lv, Jiayi Zheng, Junxiang Cai et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis estimated long-term mortality among children with sepsis diagnosed using international consensus criteria. Six studies, including 11,318 pediatric patients, contributed data. The pooled long-term mortality was 11% (95% CI: 7-16%), with substantial heterogeneity across studies (I² = 98.2%, p < 0.001). Sensitivity analyses produced similar estimates, and the authors found limited evidence of publication bias. The review highlights mortality risk after hospital discharge and calls for stronger longitudinal research to identify modifiable risks and inform follow-up care.

Key findings

  • Across six studies and 11,318 pediatric sepsis patients, pooled long-term mortality was 11% (95% CI: 7-16%).
  • Estimates showed substantial between-study heterogeneity (I² = 98.2%, p < 0.001).
  • Sensitivity analyses yielded similar results, and evidence of publication bias was limited.

Why it matters

Mortality after pediatric sepsis extends beyond the hospital stay, underscoring that discharge does not mark the end of risk. The pooled estimate provides a broad measure of this burden, while the marked variation between studies cautions against assuming a uniform prognosis. Better longitudinal evidence may help clarify which survivors are at greatest risk and what follow-up needs are appropriate.

What to keep in mind

The pooled estimate is based on only six studies and has substantial heterogeneity (I² = 98.2%), limiting confidence that it represents a consistent risk across populations or settings.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.